Author

Simeng Wang

Observed names: S. C. Wang, S.-C. Wang, Wang, Simeng

Institution: Anhui Medical University

Observed institutions: National Yang Ming Chiao Tung University, Anhui Medical University, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an Jiaotong University

ORCID: 0000-0002-2714-2821

Observed ORCID: 0000-0002-2714-2821

OpenAlex ID: A5083454681

Advancing Cancer Immunotherapy through Engineering New PD-L1 Degraders: A Comprehensive Study from Small Molecules to PD-L1-Specific Peptide–Drug Conjugates

2024 · Zekun Zeng, Zhiwei Yang, et al. · Journal of Medicinal Chemistry · 19

Enhanced electron-hole plasma stimulated emission in optically pumped gallium nitride nanopillars

2011 · M.-H. Lo, Y.-J. Cheng, et al. · Applied Physics Letters · 13

Engineering PD-L1 targeted liposomal canagliflozin achieves multimodal synergistic cancer therapy

2024 · Simeng Wang, Mengjun Sui, et al. · Chemical Engineering Journal · 10

Harnessing transcription factor-driven ROS for synergistic multimodal lung cancer treatment

2024 · Ye Zhou, Simeng Wang, et al. · Journal of Controlled Release · 9

Span Value as a Critical Quality Attribute for PLGA Microspheres: Controlling Burst Release and Enhancing Therapeutic Efficacy via Wet Sieving

2026 · Lele Wang, Wenqiang Liu, et al. · Pharmaceutics · 4

Spectrally resolved spontaneous emission patterns of oxide-confined vertical-cavity surface-emitting lasers

2004 · T. C. Lu, W. C. Hsu, et al. · Journal of Applied Physics · 2

pH-Activatable engineered nanoparticle-based selective hexokinase 2 degrader provokes GSDME-dependent pyroptosis for cancer therapy

2025 · Linlin Gong, Shasha Li, et al. · Acta Pharmaceutica Sinica B · 1

A tumor-responsive nanostrategy for reducing the risk of immunotherapy-related myocarditis

2024 · Mengjun Sui, Simeng Wang, et al. · Chemical Engineering Journal · 1

Works count: 12

Citation count: 59

H-index: 4

I10-index: 3